This proposal seeks to discover a new gene(s) within a candidate region on chromosome 1p that modifies PD susceptibility and/or age at onset. The characterization of such a gene, and the pathways in which it participates, will further our understanding of the molecular events that lead to selective neurodegeneration in PD. This knowledge might serve to identify novel therapeutic targets which could be used to prevent and better treat the disease.
Parkinson's disease (PD) affects 1-2% of the population over 60 years of age and thus constitutes a major problem in public health. Current treatment strategies are only palliative and a better understanding of the molecular mechanisms underlying PD is necessary in order to develop more definitive neuroprotective therapies. Human genetic studies are a valuable tool in this endeavor. A new candidate region for PD was recently identified on chromosome 1p in two independent linkage studies. However, the identity of the disease gene(s) within this region has not yet been determined. In this application, we propose to fine-map the candidate interval using 7,600 single nucleotide polymorphisms (SNPs) in 300 multiplex PD families recruited from across the United States. FBAT- based methods will be utilized to identify SNPs which modify PD risk or age at onset. Exploratory analyses will be undertaken to test for gene x environment interactions. We will then validate markers which meet a pre-defined significance threshold in an independent case control sample of 2,000 subjects. Finally, an extensive bioinformatics analysis will be performed to assemble a list of putative functional risk variants which will subsequently be tested for effects on gene expression and/or protein function via in vitro assays. This work has the potential to discover a new disease gene(s) which could provide important insights into the pathogenesis of PD that ultimately translate into improved strategies for diagnosis, prevention, and treatment.
|Stewart, Tessandra; Sui, Yu-Ting; Gonzalez-Cuyar, Luis F et al. (2014) Cheek cell-derived *-synuclein and DJ-1 do not differentiate Parkinson's disease from control. Neurobiol Aging 35:418-20|
|Millard, Steven P; Lutz, Franziska; Li, Ge et al. (2014) Association of cerebrospinal fluid A*42 with A2M gene in cognitively normal subjects. Neurobiol Aging 35:357-64|
|Wan, Jia Y; Edwards, Karen L; Hutter, Carolyn M et al. (2014) Association mapping of the PARK10 region for Parkinson's disease susceptibility genes. Parkinsonism Relat Disord 20:93-8|
|Cholerton, Brenna A; Zabetian, Cyrus P; Wan, Jia Y et al. (2014) Evaluation of mild cognitive impairment subtypes in Parkinson's disease. Mov Disord 29:756-64|
|Perandones, C; Giugni, J C; Calvo, D S et al. (2014) Mosaicism of alpha-synuclein gene rearrangements: report of two unrelated cases of early-onset parkinsonism. Parkinsonism Relat Disord 20:558-61|
|Hatano, Taku; Funayama, Manabu; Kubo, Shin-ichiro et al. (2014) Identification of a Japanese family with LRRK2 p.R1441G-related Parkinson's disease. Neurobiol Aging 35:2656.e17-23|
|Mata, Ignacio F; Leverenz, James B; Weintraub, Daniel et al. (2014) APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. JAMA Neurol 71:1405-12|
|Shi, Min; Liu, Changqin; Cook, Travis J et al. (2014) Plasma exosomal ?-synuclein is likely CNS-derived and increased in Parkinson's disease. Acta Neuropathol 128:639-50|
|Burdick, Daniel J; Cholerton, Brenna; Watson, G S et al. (2014) People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance. Mov Disord 29:1258-64|
|Mata, Ignacio F; Alvarez, Victoria; Ribacoba, Renee et al. (2013) Novel Lrrk2-p.S1761R mutation is not a common cause of Parkinson's disease in Spain. Mov Disord 28:248|
Showing the most recent 10 out of 29 publications